TITRATION

Flexible, once-daily dosing options to take patients through their treatment journey1

XCOPRI® (CENOBAMATE TABLETS) CV IS TITRATED AT 2-WEEK INTERVALS1

WEEKS 1-2

12.5 mg

once daily

XCOPRI Epilepsy Medication 12 mg Tablet

WEEKS 3-4

25 mg

once daily

XCOPRI Epilepsy Medication 25 mg Tablet

WEEKS 5-6

50 mg

once daily

XCOPRI Epilepsy Medication 50 mg Tablet

WEEKS 7-8

100 mg

once daily

XCOPRI Epilepsy Medication 100 mg Tablet

WEEKS 9-10

150 mg

once daily

XCOPRI Epilepsy Medication 150 mg Tablet

WEEK 11 &
THEREAFTER

200 mg

once daily

(recommended
maintenance dosage)

XCOPRI Epilepsy Medication 200 mg Tablet

Not actual sizes.

XCOPRI can be prescribed as monotherapy or adjunctive therapy1

Maximum dosage: If needed based on clinical response and tolerability, dosage may be increased above 200 mg/day by increments of 50 mg/day every 2 weeks to a maximum of 400 mg/day.1

For patients with mild or moderate hepatic impairment, the maximum recommended dosage is 200 mg once daily. XCOPRI is not recommended for use in patients with severe hepatic impairment.1

See Prescribing Information for additional Dosage and Administration instructions.

In an open-label study, when XCOPRI was titrated at 2-week intervals, there were no reported cases of drug reaction with eosinophilia and systemic symptoms (DRESS). This finding does not establish that the risk of DRESS is prevented by a slower titration; however, XCOPRI should be initiated at 12.5 mg once daily and titrated every 2 weeks.1

MAINTENANCE

Raise your expectations to the possibility of ZERO seizures1

285,482 PRESCRIPTIONS HAVE BEEN WRITTEN TO DATE FOR XCOPRI2*

Get your patients started today!

XCOPRI Titration Blister Packs

Designed to simplify the titration schedule of XCOPRI. At-a-glance
instructions have been included to assist you and your patients as
XCOPRI doses are increased over time.1

XCOPRI HCP Cenobamate Tablets Titration Blister Packs 12.5 | 25 mg
12.5 mg / 25 mg (28-day supply)
XCOPRI Cenobamate Epilepsy Medication Tablets 50 mg & 100 mg Titration Blister Packs
50 mg / 100 mg (28-day supply)
XCOPRI Cenobamate Epilepsy Medication Tablets 150 mg & 200 mg Titration Blister Packs
150 mg / 200 mg (28-day supply)

XCOPRI Maintenance Blister Packs and Bottles

Designed to give you the flexibility to find the XCOPRI dosage
that is right for your individual patients.1

XCOPRI Cenobamate Epilepsy Medication Tablets 250 mg Titration Blister Pack

Maintenance blister
packs available:
• 250 mg [28-day supply]
• 350 mg [28-day supply]

XCOPRI Cenobamate Epilepsy Medication Tablets Bottle 50mg & 200mg

Maintenance bottles available:
• 50 mg (30-count bottle)
• 100 mg (30-count bottle)
• 150 mg (30-count bottle)
• 200 mg (30-count bottle)

Request Samples from a Rep

How to Prescribe from Titration Phase to Maintenance Dosing

Below is an example† of a titration schedule for prescribing XCOPRI. After you have titrated up to find the right maintenance dose, maintenance blister packs and bottles are available.1

XCOPRI Cenobamate Epilepsy Medication Prescription Example Titration Schedule 12.5mg/25mg
XCOPRI Cenobamate Epilepsy Medication Prescription Example Titration Schedule 50mg/100mg
XCOPRI Cenobamate Epilepsy Medication Prescription Example Titration Schedule 150mg/200mg
XCOPRI Cenobamate Epilepsy Medication Prescription Example Titration Schedule 200mg
Download Additional Dosing InformationExplore Resources
*Total US prescriptions as of January 2022. Source: IQVIA.
†While 200 mg is the recommended maintenance dosage, dosing can vary based on clinical response and tolerability. Dosage may be increased above 200 mg/day by increments of 50 mg/day every 2 weeks to a maximum of 400 mg/day.1
References: 1. XCOPRI (package insert). Paramus, NJ: SK Life Science, Inc. 2. Data on File. SK Life Science, Inc.
Expand

INDICATION

XCOPRI® (cenobamate tablets) CV is indicated for the treatment of partial-onset seizures in adult patients.

Important Safety Information
and indication

CONTRAINDICATIONS
XCOPRI® is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.

XCOPRI is contraindicated in patients with Familial Short QT syndrome.

For US Healthcare Professionals Only
For US Healthcare Professionals Only
Close IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION and INDICATION for XCOPRI® (cenobamate tablets) CV

CONTRAINDICATIONS

XCOPRI® is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.

XCOPRI is contraindicated in patients with Familial Short QT syndrome.

WARNINGS AND PRECAUTIONS

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including XCOPRI. DRESS has been reported, including one fatality, when XCOPRI is titrated rapidly (weekly or faster titration). No cases of DRESS were reported in an open-label safety study of 1339 partial-onset seizure patients when XCOPRI was initiated at 12.5 mg/day and titrated every two weeks. This finding does not establish that the risk of DRESS is prevented by a slower titration; however, XCOPRI should be initiated at 12.5 mg once daily and titrated every two weeks. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement. Eosinophilia is often present. If such signs or symptoms are present, the patient should be evaluated immediately. XCOPRI should be discontinued immediately and not restarted if an alternative etiology for the signs or symptoms cannot be established.

QT Shortening: XCOPRI can cause shortening of the QT interval. Caution should be used when administering XCOPRI and other drugs that shorten the QT interval as there may be a synergistic effect on the QT interval that would increase the QT shortening risk.

Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including XCOPRI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Advise patients, their caregivers, and/or families to be alert for these behavioral changes and report them immediately to a healthcare provider.

Neurological Adverse Reactions: XCOPRI causes dose-dependent increases in the neurologic adverse reactions including, dizziness, diplopia, disturbance in gait and coordination, somnolence, and fatigue.

Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of XCOPRI is known.

Withdrawal of AEDs: As with all antiepileptic drugs, XCOPRI should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. But if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered.

MOST COMMON ADVERSE REACTIONS

In adult adjunctive therapy placebo-controlled clinical studies, the most common adverse reactions that occurred in XCOPRI-treated patients (incidence at least 10% and greater than placebo) were somnolence, dizziness, fatigue, diplopia, headache.

DOSING CONSIDERATIONS

Dosage adjustment of XCOPRI or other concomitant medications may be necessary.

  • Consider gradually reducing phenytoin dosages by up to 50% during initial titration.
  • Consider reducing dosages of phenobarbital and clobazam as needed when used concomitantly with XCOPRI. When XCOPRI and carbamazepine or lamotrigine are taken concomitantly, consider increasing dosages as needed of carbamazepine or lamotrigine.
  • Consider increasing dosages as needed of drugs which are CYP2B6 and CYP3A substrates and decreasing dosages as needed of drugs which are CYP2C19 substrates.
  • Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control.

Dosage reduction of XCOPRI may be considered in patients with mild to moderate and severe renal impairment. XCOPRI use is not recommended in end‑stage renal disease.

The maximum recommended daily dose is 200 mg for patients with mild or moderate hepatic impairment. XCOPRI use is not recommended in patients with severe hepatic impairment

DRUG ABUSE

XCOPRI is a Schedule V controlled substance.

INDICATION

XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.

Please see Full Prescribing Information.